LMS, short for leiomyosarcoma, is a cancer that starts in smooth muscle cells, the type of muscle you don’t consciously control. Smooth muscle lines the walls of your uterus, stomach, intestines, blood vessels, and other organs. LMS accounts for 10% to 20% of all soft tissue sarcomas, making it one of the more common subtypes of this already rare cancer group.
Because smooth muscle exists throughout the body, LMS can develop in many locations. The most frequent sites are the retroperitoneum (the space behind the abdominal organs), the uterus, and the limbs, in that order. It tends to be aggressive and can be difficult to diagnose early because its symptoms often mimic less serious conditions.
Where LMS Develops and Why Location Matters
The location of a leiomyosarcoma shapes nearly everything about the experience: what symptoms appear first, how it’s found, and how it’s treated. Retroperitoneal tumors grow in the deep space behind the abdomen, where they can reach a large size before pressing on surrounding organs enough to cause noticeable problems. Symptoms from these tumors are often vague, like abdominal fullness, back pain, or a feeling of pressure.
Uterine LMS is the form most commonly discussed because of a specific diagnostic challenge. It grows within the muscular wall of the uterus and can look nearly identical to a benign fibroid (leiomyoma) on initial evaluation. A uterine mass that was previously thought to be a fibroid but keeps growing after menopause, when fibroids typically shrink, should raise concern. LMS of the limbs usually presents as a painless, enlarging mass in the thigh or other soft tissue areas, and tends to be noticed earlier simply because it’s closer to the surface.
LMS vs. Fibroids: A Critical Distinction
Uterine fibroids are extremely common and almost always benign. LMS is rare. But distinguishing one from the other before surgery is genuinely difficult, and the stakes are high. If a mass is mistakenly treated as a fibroid, a patient with LMS could face delayed diagnosis and inappropriate management. On the other hand, overcalling an unusual fibroid as cancer could lead to unnecessary extensive surgery.
MRI is the best imaging tool for telling them apart. Radiologists look for several features that lean toward LMS: irregular or poorly defined borders (seen in 80% to 100% of sarcomas versus under 4% of atypical fibroids), areas of tissue death inside the tumor that don’t take up contrast dye (present in about 80% of LMS cases), and signs of bleeding within the mass. Internal hemorrhage alone has a sensitivity of 95% to 100% and specificity of 82% to 95% for LMS. Typical fibroids, by contrast, appear dark on certain MRI sequences with smooth, well-defined edges.
Even with these imaging clues, there’s overlap. Some cellular fibroids can mimic the appearance of LMS, and a definitive diagnosis ultimately requires examining the tissue under a microscope after removal.
Symptoms to Be Aware Of
LMS often causes nonspecific symptoms, meaning the problems it creates come from the tumor physically pushing against nearby structures rather than from the cancer invading them early on. This is part of why diagnosis is frequently delayed.
- Uterine LMS: Abnormal vaginal bleeding (especially after menopause), pelvic pain or pressure, and a rapidly enlarging pelvic mass.
- Retroperitoneal LMS: Vague abdominal or back pain, a sense of fullness, weight loss, or a palpable mass in the abdomen.
- Limb LMS: A painless, growing lump in the thigh, calf, or upper arm. Pain may develop as the tumor enlarges and presses on nerves.
None of these symptoms point specifically to LMS on their own, which is why many patients are initially evaluated for more common conditions before the true diagnosis is made.
How LMS Is Diagnosed
Diagnosis starts with imaging, typically MRI or CT scans, followed by a biopsy where a small sample of the tumor is examined under a microscope. Under the microscope, LMS cells have a characteristic spindle shape and are arranged in interlocking bundles that resemble normal smooth muscle tissue. Pathologists confirm the diagnosis by testing for specific proteins that smooth muscle cells produce, including markers called smooth muscle actin, desmin, and h-caldesmon. A tumor that tests positive for these markers and shows signs of aggressive cell growth is classified as LMS.
One important biological feature: about 90% of LMS tumors carry mutations in a tumor suppressor gene called RB1. LMS also has a relatively low number of overall mutations compared to many other cancers, which partly explains why it responds poorly to certain newer treatments like immunotherapy.
Treatment for Localized Disease
Surgery is the primary treatment for LMS that hasn’t spread. The goal is to remove the entire tumor with a margin of healthy tissue around it. For tumors in the limbs, body wall, or head and neck region, radiation therapy is often considered alongside surgery, particularly for high-grade tumors. When radiation is used, delivering it before surgery is generally preferred over after. If the surgeon wasn’t able to remove the tumor completely (positive margins), radiation becomes especially important.
For uterine LMS, the standard approach is typically a hysterectomy. Unlike some uterine cancers, LMS of the uterus responds to estrogen and progesterone receptors in only about 40% and 38% of cases respectively, which limits the role of hormonal therapy compared to other gynecologic cancers.
Treatment for Advanced or Metastatic LMS
When LMS has spread to distant sites, typically the lungs, liver, or bones, chemotherapy becomes the cornerstone of treatment. The most evidence-supported first-line approach uses doxorubicin-based regimens.
The strongest results to date come from combining doxorubicin with trabectedin, followed by trabectedin maintenance. In clinical trials, this combination produced tumor shrinkage in about 37% of patients, with a median time before the cancer progressed of just over 12 months. The two-year survival rate was 68%, compared to 49% for doxorubicin alone. Another effective combination pairs doxorubicin with dacarbazine, which showed a response rate of about 31% and a median overall survival of nearly 37 months in matched analyses.
For patients who can’t tolerate doxorubicin-based treatment, gemcitabine combined with docetaxel is a reasonable alternative, though results are more modest, with a median overall survival of about 18 months.
Standard immunotherapy has been largely disappointing for LMS. In the SARC028 trial, none of the LMS patients responded to the checkpoint inhibitor pembrolizumab. This is consistent with LMS’s low mutation burden, which means the immune system has fewer abnormal proteins to recognize and attack. However, a small subset of patients, particularly those with uterine LMS, carry defects in DNA repair genes that may make them candidates for a class of drugs called PARP inhibitors. Uterine LMS has one of the highest rates of these DNA repair deficiencies among all tumor types, and early-phase studies combining PARP inhibitors with other agents have shown promise in this selected group.
Survival Rates and Outlook
Prognosis for LMS varies dramatically depending on how far the cancer has spread at diagnosis. Five-year relative survival rates for uterine LMS, based on data from women diagnosed between 2015 and 2021, illustrate this clearly:
- Localized (confined to the uterus): 61%
- Regional (spread to nearby structures or lymph nodes): 28%
- Distant (spread to lungs, liver, bones, or other distant sites): 13%
- All stages combined: 38%
These numbers reflect averages across many patients and don’t account for individual factors like tumor grade, the specific genetic profile of the cancer, or how well it responds to treatment. LMS is a highly heterogeneous cancer, meaning two tumors that look similar under the microscope can behave very differently. This unpredictability is one of the most challenging aspects of the disease for both patients and oncologists, and it’s why treatment decisions for LMS are best made by a multidisciplinary team with sarcoma expertise.